WallStreetZenWallStreetZen

NASDAQ: CRDF
Cardiff Oncology Inc Stock

$2.47+0.26 (+11.76%)
Updated Jul 11, 2024
CRDF Price
$2.47
Fair Value Price
$0.10
Market Cap
$110.47M
52 Week Low
$0.94
52 Week High
$6.42
P/E
-2.74x
P/B
1.81x
P/S
391.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$610.00k
Earnings
-$40.23M
Gross Margin
100%
Operating Margin
-6,594.92%
Profit Margin
-6,598.9%
Debt to Equity
0.22
Operating Cash Flow
-$30M
Beta
1.18
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CRDF Overview

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRDF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRDF ($2.47) is overvalued by 2,428.01% relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRDF ($2.47) is not significantly undervalued (2,428.01%) relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRDF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRDF due diligence checks available for Premium users.

Be the first to know about important CRDF news, forecast changes, insider trades & much more!

CRDF News

Valuation

CRDF fair value

Fair Value of CRDF stock based on Discounted Cash Flow (DCF)
Price
$2.47
Fair Value
$0.10
Overvalued by
2,428.01%
CRDF ($2.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRDF ($2.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRDF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CRDF price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.74x
Industry
-14.46x
Market
31.84x

CRDF price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.81x
Industry
6.37x
CRDF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CRDF's financial health

Profit margin

Revenue
$205.0k
Net Income
-$10.0M
Profit Margin
-4,886.3%
CRDF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRDF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$74.0M
Liabilities
$13.1M
Debt to equity
0.22
CRDF's short-term assets ($69.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRDF's short-term assets ($69.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRDF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRDF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.7M
Investing
$4.6M
Financing
$107.0k
CRDF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CRDF vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CRDF$110.47M+11.76%-2.74x1.81x
ATYR$111.80M-3.57%-1.80x1.32x
CTMX$109.09M+6.87%7.00x-3.44x
ARMP$108.46M+11.94%-1.36x-1.92x
KPTI$113.24M+10.96%-0.76x-0.67x

Cardiff Oncology Stock FAQ

What is Cardiff Oncology's quote symbol?

(NASDAQ: CRDF) Cardiff Oncology trades on the NASDAQ under the ticker symbol CRDF. Cardiff Oncology stock quotes can also be displayed as NASDAQ: CRDF.

If you're new to stock investing, here's how to buy Cardiff Oncology stock.

What is the 52 week high and low for Cardiff Oncology (NASDAQ: CRDF)?

(NASDAQ: CRDF) Cardiff Oncology's 52-week high was $6.42, and its 52-week low was $0.94. It is currently -61.53% from its 52-week high and 162.77% from its 52-week low.

How much is Cardiff Oncology stock worth today?

(NASDAQ: CRDF) Cardiff Oncology currently has 44,724,591 outstanding shares. With Cardiff Oncology stock trading at $2.47 per share, the total value of Cardiff Oncology stock (market capitalization) is $110.47M.

Cardiff Oncology stock was originally listed at a price of $1,620.00 in Jul 27, 2004. If you had invested in Cardiff Oncology stock at $1,620.00, your return over the last 19 years would have been -99.85%, for an annualized return of -28.92% (not including any dividends or dividend reinvestments).

How much is Cardiff Oncology's stock price per share?

(NASDAQ: CRDF) Cardiff Oncology stock price per share is $2.47 today (as of Jul 11, 2024).

What is Cardiff Oncology's Market Cap?

(NASDAQ: CRDF) Cardiff Oncology's market cap is $110.47M, as of Jul 12, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cardiff Oncology's market cap is calculated by multiplying CRDF's current stock price of $2.47 by CRDF's total outstanding shares of 44,724,591.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.